BrainParrot

India rejects patent plea for the treatment of drug-resistant TB

GS3Full notePublished: · Updated:

Source: The Hindu, 29 October 2026

Summary

  • The Indian Patent Office rejected a patent application by the U.S.-based Global Alliance for TB Drug Development (TB Alliance) for BPaL, a six-month, all-oral regimen of bedaquiline, pretomanid and linezolid for drug-resistant TB.
  • The decision followed two pre-grant oppositions filed in 2020 by TB patient and civil society groups. They argued that the combination, and its use in a shorter regimen, had already been disclosed in scientific research dating back to 2015, so it lacked an inventive step.
  • Civil society groups now want TB Alliance to stop pursuing proprietary rights over BPaL in other countries.

UPSC relevance: GS3 — S&T: IPR; GS2 — Governance: health, access to medicines

Key facts for Prelims

  • Section 25(1), Patents Act 1970 = pre-grant opposition. Section 2(1)(j) = invention. Section 2(1)(ja) = inventive step. Section 3(d) = bars patents on new forms of known substances without enhanced efficacy (anti-evergreening).
  • Patent term in India = 20 years from the date of application.
  • Prior art disclosed before filing can defeat both novelty and inventive step.
  • BPaL = bedaquiline + pretomanid + linezolid (6 months, all-oral). BPaLM adds moxifloxacin.
  • TB Alliance is a U.S.-based Global Alliance for TB Drug Development.
  • Parties in the case: Sankalp Rehabilitation Trust (Eldred Tellis), Ganesh Acharya, Lawyers' Collective, MSF Access Campaign, Delhi Network of Positive People (DNP+) and TWN.
  • India has the world's highest TB burden. WHO classifies India among the high-burden countries for TB, HIV-associated TB and MDR/RR-TB.

Data and details

  • Burden: About 2.71 million people developed TB in India in 2024 (WHO estimate), roughly a quarter of global cases, with an incidence of 187 per 1,00,000.
  • Oppositions: Two pre-grant oppositions were filed in 2020. One was by Eldred Tellis (Sankalp Rehabilitation Trust) and Ganesh Acharya, backed by Lawyers' Collective and MSF Access Campaign. The other was by DNP+, backed by TWN.
  • Grounds: The combination and its use in a shorter regimen had been disclosed in scientific research dating to 2015, and combining known medicines does not create an inventive step warranting a new monopoly.
  • Regimen: BPaL is recommended by WHO for eligible people and is a six-month all-oral course. The article contrasts it with older regimens of more than a year with painful injections, per Loon Gangte of DNP+.
  • Next step: Civil society wants TB Alliance to stop pursuing proprietary rights over BPaL in other countries.

Static–dynamic linkage

  • Under India's Patents Act, 1970, a patent requires novelty, an inventive step and industrial applicability. A combination of already-known medicines does not qualify just because they are combined, unless it is a non-obvious technical advance.
  • Section 3(d) and the inventive-step standard together stop "evergreening", the practice of extending monopoly through minor modifications of known drugs. This balances innovation incentives with access to affordable medicines.
  • Pre-grant opposition lets any person put prior-art material before the Controller before a patent is granted. It is a tool civil society uses to keep drugs open to generic production.

Syllabus mapping: GS3 — S&T: Intellectual Property Rights (IPR) issues; GS2 — Governance/Health: access to medicines, health sector; GS2 — IR: TRIPS flexibilities (background).

Background primer

Patents Act, 1970 – inventive step and pre-grant opposition

What it is:
India's statute governing patents. Section 2(1)(j) defines "invention" as a new product or process involving an inventive step and capable of industrial application. Under Section 2(1)(ja), an inventive step means a feature that is not obvious to a person skilled in the art.
Founded:
The Act was enacted in 1970 (in force from 1972) to improve access to affordable medicines. For food, drugs and chemicals it recognised only process patents, not product patents. The 2005 amendment introduced product patents for pharmaceuticals in line with TRIPS and added Section 3(d) as an anti-evergreening safeguard.
Members:
The Office of the Controller General of Patents, Designs and Trade Marks (the "Indian Patent Office"). Controllers examine and decide applications.
Mandate:
Pre-grant opposition under Section 25(1) allows any person to oppose a patent application after publication and before the patent is granted. Section 3(d) bars patents on minor modifications of known substances, which checks evergreening.
Why it matters:
Balance TRIPS-compliant product patents with public health access.

BPaL / BPaLM regimen

What it is:
A short, all-oral regimen for drug-resistant TB. BPaL combines bedaquiline, pretomanid and linezolid over six months. BPaLM adds moxifloxacin.
Mandate:
BPaLM has been introduced under the national programme to reduce duration to 6 months, and more than 15,000 MDR/RR-TB patients have been initiated on it.

Additional context

  • GKToday dates the Patent Office rejection to 27 October 2026. It says the civil society pre-grant oppositions were filed in July 2020. It adds that the Patent Office cited lack of novelty, absence of an inventive step, non-patentability and insufficient disclosure. It also notes that the decision rejects this particular application and does not by itself end all other patent rights or regulatory requirements for the medicines.
  • TB Alliance holds 11 active BPaL-related patents in countries including Armenia, Azerbaijan and South Africa, set to expire in 2036. The Indian rejection means this application did not result in a patent grant in India.
  • WHO's Global TB Report 2025 puts India at 32% of the global total of people who developed MDR/RR-TB in 2024. India's national TB elimination goal was 2025, five years ahead of the global target of 2030.

Mains dimensions

  • Public health vs. IP monopoly: A patent on a combination of already-known TB drugs would have let one entity control the supply of a WHO-recommended regimen in the country with the world's largest TB burden. Rejection of this application means no Indian patent grant on it, which removes one barrier to generic production of the regimen. It does not by itself settle every other patent or regulatory question on the component drugs.
  • Legal logic: The opposition rested on prior disclosure in 2015 research and the lack of an inventive step, not on any public-health exception. This shows the strength of the statutory patentability criteria. Section 3(d) is the related anti-evergreening safeguard in Indian law.
  • Role of civil society: Patient networks (DNP+), lawyers' groups and MSF used pre-grant opposition. The process took from 2020 to 2026, so timeline and administrative capacity are also relevant.
  • Patient-centred outcomes: Shorter, oral, injection-free treatment reduces the burden on patients and families, helping them return to work and care for families, per the patient advocate quoted.
  • Global spillovers: The article notes that the debate extends to other countries where TB Alliance pursues rights. India's decision becomes a reference for opposition elsewhere, though it is not binding abroad.
  • TB elimination: With a quarter of global TB cases, India's treatment cost and availability directly affect elimination targets.

Possible Mains question

**GS3/GS2, 15 marks:** "How do India's patent law provisions on inventive step, pre-grant opposition and Section 3(d) balance innovation incentives with access to affordable medicines? Illustrate with reference to drug-resistant TB treatment."

Related topics

  • Novartis v. Union of India (2013) and Section 3(d); compulsory licensing (Section 84) and TRIPS flexibilities, Doha Declaration
  • National TB Elimination Programme, TB Mukt Bharat Abhiyaan, Ni-kshay Poshan Yojana
  • Drug-resistant TB categories: MDR, XDR, RR-TB
  • Voluntary licensing, patent pools and generic competition

Topics: GS3Sci & Tech

How we write and check these notes →

All current affairs of 29 October 2026 → · UPSC Current Affairs